Press releases

29 May, 2020

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announced an increase of the number of shares and votes in Abliva of 83,720,875 as a result of a fully performed preferential rights issue, resolved by the Boa ...

28 May, 2020

NeuroVive Pharmaceutical changes its name to Abliva

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) announced today that the company’s application for a change of name to Abliva AB (publ) has been approved by the Swedish Companies Registration Offi ...

20 May, 2020

Regulatory

Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today on 20 May 2020 held its Annual General Meeting (AGM). A summary of the resolutions follows.

20 May, 2020

Last day of trading with BTA in NeuroVive

The rights issue in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”) has today been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed sh ...

20 May, 2020

Regulatory

Interim Report January-March 2020

Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

28 April, 2020

Regulatory

NeuroVive’s Nomination Committee amends its proposal to the 2020 Annual General Meeting

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the Company's Nomination Committee in its proposal to the Annual General Meeting May 20, 2020, added a proposal regarding an ad ...

24 April, 202019 February, 2024

Regulatory

Publication of supplementary prospectus related to NeuroVive’s rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...

23 April, 2020

Regulatory

NeuroVive Pharmaceutical AB publishes 2019 Annual report

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.

22 April, 2020

NeuroVive’s Board Members and Senior Executives subscribe to shares in the ongoing rights issue

In the ongoing rights issue in NeuroVive, the Board and Senior Executives have undertaken to subscribe for at least 446,176 shares.

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...

20 April, 2020

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Wednesday, 20 May 2020 at Medicon V ...